Antibody-drug conjugates (ADCs) as a therapeutic modality has received renewed interests in this decade due to recent clinical successes. ADC achieves targeted drug delivery by combining potency of cytotoxic drugs with target selectivity of monoclonal antibodies. The antibody recognizes the target antigen, binds and is then internalized into cancer cells. The linker provides controlled release of cytotoxic drugs.